What are the annual ischemic stroke risks for each CHADS‑VASc score, including differences between men and women?

Annual Stroke Risk by CHA₂DS₂-VASc Score

The annual ischemic stroke risk increases progressively with each CHA₂DS₂-VASc score point, ranging from 0% at score 0 to over 15% at score 9, with clinically significant differences between men and women at intermediate scores. 1, 2

Stroke Risk by Score Category

Low Risk (Score 0-1)

• Score 0: 0-0.6% annual stroke risk—represents truly low risk in both men and women 1, 2, 3
• Score 1: 0.6-1.3% annual stroke risk, though this varies considerably by validation cohort (range 0.5-2.9%) 2, 3, 4
  • Women with score 1 (from sex alone) have similar low risk to men with score 0 1, 3
  • Age 65-74 years as the sole risk factor confers higher stroke risk (1.22% in women, 1.02% in men) than female sex alone 5, 4

Moderate Risk (Score 2-3)

• Score 2: 1.6-2.2% annual stroke risk—this is the critical threshold where oral anticoagulation becomes strongly recommended 1, 2, 3
• Score 3: 3.2-5.3% annual stroke risk, representing high risk requiring anticoagulation 1, 2

High Risk (Score 4-9)

• Score 4: 4.0-8.2% annual stroke risk 1, 2
• Score 5: 3.2-6.7% annual stroke risk 1, 2
• Score 6: 3.6-9.8% annual stroke risk 1, 2
• Score 7: 8.0-9.6% annual stroke risk 1, 2
• Score 8: 6.7-11.1% annual stroke risk 1, 2
• Score 9: ≥15.2% annual stroke risk 1, 2

Sex-Specific Differences in Stroke Risk

Women demonstrate 20-30% higher stroke risk than men after adjusting for other risk factors, but this difference is primarily driven by age rather than sex itself. 6, 5

Key Sex-Related Findings

• Women with AF have worse stroke severity and more permanent disability after stroke compared to men 6
• The increased stroke risk in women is most pronounced at CHA₂DS₂-VA scores ≥2 (risk ratio 1.72 for women vs. men) 7
• Women show greater stroke risk than men specifically at age >70 years (interaction P=0.007) 7
• When divided into age groups, the sex-based differences in stroke rates are substantially attenuated, suggesting age is the primary confounding factor 5

Clinical Implications for Women

• The 2019 AHA/ACC/HRS guidelines increased the anticoagulation threshold for women from CHA₂DS₂-VASc ≥2 to ≥3, while maintaining the threshold at ≥2 for men 6
• Female sex functions as a risk modifier rather than an independent risk factor—it amplifies stroke risk in women who already have ≥2 additional risk factors 8
• Women without other risk factors (score 1 from sex alone) have truly low risk similar to men with score 0 and do not require anticoagulation 1, 3

Contemporary Risk Stratification: CHA₂DS₂-VA vs. CHA₂DS₂-VASc

The 2024 European Society of Cardiology guidelines now recommend the CHA₂DS₂-VA score (excluding sex category) as the primary risk stratification tool, with anticoagulation recommended for scores ≥2. 1, 9

CHA₂DS₂-VA Score Thresholds

• Score 0: No anticoagulation recommended (Class I) 1
• Score 1: Consider anticoagulation with shared decision-making (Class IIa)—approximately 15% of AF patients fall into this intermediate-risk group 1
• Score ≥2: Oral anticoagulation strongly recommended (Class I), with DOACs preferred over warfarin 1

Comparison of Scoring Systems

• The CHA₂DS₂-VA and CHA₂DS₂-VASc scores show similar discriminative ability (C-statistics 0.647 vs. 0.655, P=0.258) 7
• Both scores have modest predictive accuracy overall (C-statistic 0.6-0.7) 6, 1
• The CHA₂DS₂-VASc score reclassifies 26% of patients with CHADS₂ score of 1 to low annual stroke risk of approximately 1%, potentially allowing withholding of anticoagulation 4

Real-World Validation Data

Japanese registry data from 9,733 non-anticoagulated AF patients demonstrated clear risk stratification by CHA₂DS₂-VASc score over 2.5 years of follow-up. 10

Annual Stroke Incidence by Risk Category

• Low risk (men score 0, women score 1): 0.18% annual stroke rate 10
• Intermediate risk (men score 1, women score 2): 0.44% annual stroke rate 10
• High risk (men ≥2, women ≥3): 1.29% annual stroke rate 10
• Overall annual stroke rate in untreated patients: 0.58% 10

Critical Clinical Pitfalls

Common Scoring Errors

• Age miscalculation: Age 65-74 receives 1 point; age ≥75 receives 2 points (total 2, not 3) 1
• Underestimating age 65-74: This age category confers higher stroke risk than other single-point risk factors and is often underappreciated 5, 4
• Overestimating female sex: Female sex alone (without other risk factors) does not justify anticoagulation 1, 5, 8
• Missing vascular disease: Actively assess for prior MI, peripheral artery disease, or aortic plaque, as this component is frequently overlooked 1
• Static risk assessment: Stroke and bleeding risks are dynamic and change over time—scores should be regularly reassessed, particularly every 2 years for accurate prediction 11

Treatment Decision Algorithm

1. Calculate CHA₂DS₂-VASc (or CHA₂DS₂-VA per 2024 ESC guidelines) 1
2. Men with score ≥2 or women with score ≥3: Initiate oral anticoagulation (Class I recommendation) 6, 1
3. Men with score 1 or women with score 2: Consider anticoagulation based on bleeding risk assessment using HAS-BLED score and shared decision-making 1, 2
4. Men with score 0 or women with score 1 (from sex alone): No anticoagulation recommended 1, 3
5. Aspirin alone or aspirin plus clopidogrel are not recommended as alternatives to anticoagulation (Class III harm) 1
6. Prefer DOACs over warfarin as first-line therapy when anticoagulation is indicated 6, 1

Special Populations Requiring Anticoagulation Regardless of Score

• Hypertrophic cardiomyopathy (Class I) 1
• Cardiac amyloidosis (Class I) 1
• Atrial flutter receives identical management to atrial fibrillation 1